Patients with PTCL-NOS (n=40), ALK- ALCL (n=23), and AITCL (n=49) were retrospectively identified using the MSKCC database. Patients had to have received CHOP based therapy as initial treatment and had PET imaging from 2001–2005, and had ≥6 months follow-up, event of progression, or death. Of the 112 identified patients, 99 had interim PET images and 90 had PET images after cycle 6. With a median follow-up of 45 months:

Median estimated OS = 93 months

Median estimated EFS = 35 months

When assessed by Deauville criteria, median OS and median EFS in patients with interim PET score of 1–3 (n=78) compared to those with a score of 4–5 (n=15) was 104 months and 64 months vs 19 months and 13 months (p<0.001)

Median EFS in patients with baseline PIT score ≤1 (n=61) compared to those with a score of >1 (n=51) was 64 months vs 24 months (p=0.019)

Median OS and median EFS in patients with baseline IPI score ≤3 (n=90) compared to those with a score of >3 (n=22) was 104 and 38 months vs 51 and 13 months (p<0.05)

This abstract presentation concluded by stating that 5-point Deauville criteria assessed interim PET carries prognostic value in patients with PTCL, more accurately identifying patients more likely to have a poorer outcome than baseline PIT and IPI score.

Reference

Abstract

Background: Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of aggressive non-Hodgkin lymphomas. The most commonly used initial treatment is CHOP-based chemotherapy often followed by consolidation with an autologous transplant. 18-fluorodeoxyglucose positron emission tomography (PET) imaging is often used to evaluate response to therapy. While the international prognostic index (IPI) and Prognostic Index for T-cell Lymphoma (PIT) can help risk stratify patients, little data exists regarding the use of interim PET using the 5-point Deauville criteria in PTCL.

Methods: We retrospectively identified patients with PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and Alk-negative anaplastic large cell lymphoma (ALK- ALCL) in the Memorial Sloan Kettering Cancer Center (MSKCC) database who were initially treated with CHOP based therapy and had PET imaging between 2001 and 2015 and had at least 6 months follow up, or an event of progression or death. Baseline, interim and end of treatment PET scans were re-read for this study using the Deauville score. Data regarding disease characteristics, relapse and survival status were collected. Event free survival (EFS) and overall survival (OS) were estimated by Kaplan-Meier method, and compared by the log rank test.

Results: 112 patients were identified with PTCL-NOS (n=40), AITL (n=49), ALK- ALCL (n=23) in the MSKCC database. Of these, 99 patients had interim PET images for review and 90 had PET images following cycle 6. The median estimated OS and EFS for the series was 93 months and 35 months respectively with a median follow up of 45 months. When evaluated by the Deauville criteria, patients with an interim PET with a score of 1-3 (n=83) had a median OS and EFS of 104 months and 64 months compared to those with a score of 4-5 (n=16) who had a median OS and EFS of 19 and 11 months (p<0.001).

In this cohort, patients with baseline PIT score ²1 (n=61) had a median EFS of 64 months compared to those with a score of >1 (n=51) who had a median EFS 24 months (p=0.019). Interim Deauville score more accurately identified patients at risk for poor outcome compared to baseline PIT score alone (p<0.001). (Figure 1A and 1B)

In this cohort, patients with baseline IPI score ²3 (n=90) had a median OS and EFS of 104 and 38 months compared to those with a score of >3 (n=22) who had a median OS and EFS of 51 and 13 months (p<0.05). Furthermore, interim Deauville further risk stratified patients compared to baseline IPI (p<0.001).

Conclusion: Interim PET when evaluated by the 5-point Deauville criteria carries prognostic value in PTCL. In this cohort, interim PET more accurately identified patients at risk of poor outcome compared to baseline IPI and PIT.

Professional society

The European Lymphoma Institute is comprised of a network of top European specialists in the field of lymphoma who are dedicated to research, training and education. Together they look to define strategies to analyse and characterize lymphoma and its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This all results in the advancement of lymphoma research and it guarantees equal access for all patients to the best possible care.